<DOC>
	<DOCNO>NCT01161940</DOCNO>
	<brief_summary>This bioequivalence study nizatidine Capsules 300 mg Dr.Reddy 's Laboratories Limited fasting condition</brief_summary>
	<brief_title>Bioequivalence Study Nizatidine Capsules 300 mg Dr.Reddy 's Laboratories Limited Under Fasting Conditions</brief_title>
	<detailed_description>Open label , balance , randomize , two-treatment , two-period , two sequence , single dose , crossover , comparative oral bioavailability study healthy , adult , male human subject fast condition .</detailed_description>
	<mesh_term>Nizatidine</mesh_term>
	<criteria>Healthy male 18 55 year age ( inclusive ) live around Ahmedabad city western part India . Having Body Mass Index ( BMI ) ≥ 18.0 kg/m2 ( calculated weight kg/ height m2 ) . Have significant disease clinically significant abnormal finding screen , medical history , physical examination , laboratory evaluation , ECG Xray recording . Able communicate effectively study personnel . Able give consent participation trial Known hypersensitivity idiosyncratic reaction nizatidine relate drug . Any disease condition might compromise haemopoietic , renal , hepatic , endocrine , pulmonary , central nervous , cardiovascular , immunological , dermatological , gastrointestinal , body system . Ingestion medication time 14 day start study . In case subject selection discretion Principal Investigator/Medical expert/coinvestigator . Any history presence asthma nasal polyp . A recent history alcoholism ( &lt; 2years ) moderate ( 180 ml/day ) alcohol use . Smokers , smoke 10 cigarettes/day refrain smoking study period . The presence clinically significant abnormal laboratory value screen . Use recreational drug history drug addiction test positive prestudy drug scan . History psychiatric disorder . A history difficulty donate blood . Donations blood ( 1 unit 450 ml ) within 90 day prior receive first dose study medication . Note : Incase blood loss ≤ 200 L , subject may dose completion 60 day blood donation ) . A positive hepatitis screen include hepatitis B surface antigen , antiHCV antiHAV antibody . A positive test result HIV antibody and/or syphilis . The receipt investigational product participation drug research study within period 90 day prior first dose study medication ( Elimination halflife study drug take consideration inclusion subject study ) . ( Note : If subject participate study blood loss ≤200 mL , subject dose completion 60 day previous study ) . An unusual diet , whatever reason ( eg. , lowsodium ) , four week prior receive study medication throughout subject , participation study . In case subject discretion Principal Investigator/Medical expert/Coinvestigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Bioavailability</keyword>
	<keyword>Nizatidine</keyword>
	<keyword>Crossover</keyword>
</DOC>